Media

News

Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

 

Updated results of Phase III trial show darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
Bayer to help young leaders fight food insecurity
Bayer responds to decision by the Institut national d’excellence en santé et en services sociaux (INESSS) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients
Bayer responds to coverage recommendation by the Pan-Canadian Oncology Drug Review (pCODR) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients
Bayer Fund helps Canadian farmers strengthen rural communities through its Canada’s Farmers Grow Communities Program
4-H Canada and Bayer Renew Five-Year Commitment to Invest in Youth through STEM
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer
Bayer Fund shares over $100,000 in funding with students through its Opportunity Scholarship Program